Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX) is a clinical-stage TechBio company developing medicines with its Recursion Operating System, an integrated platform combining automated biological experiments, proprietary data, artificial intelligence, chemistry, and clinical development. The company advances its own… From the company’s description.
Over the twelve months to Sep 30, 2026, Recursion Pharmaceuticals, Inc. reported revenue of $68.23M, up 56.2% from a year earlier, and a net loss of $475.67M. Its operating margin was −725.4%, and operations used $310.53M in cash. In fiscal 2025, it reported revenue of $74.68M, up 26.9% from fiscal 2024, and a net loss of $644.76M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Recursion Pharmaceuticals, Inc. does
In the company’s own words
Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX) is a clinical-stage TechBio company developing medicines with its Recursion Operating System, an integrated platform combining automated biological experiments, proprietary data, artificial intelligence, chemistry, and clinical development. The company advances its own drug candidates, primarily in oncology and rare diseases, and works with pharmaceutical partners to discover and develop programs across oncology, neuroscience, immunology, and other therapeutic areas. Its platform supports target discovery, small-molecule design, and clinical-trial planning; automated laboratories can run more than two million experiments per week. In 2025, Recursion had five clinical programs, including REC-4881 for familial adenomatous polyposis and REC-617 for advanced solid tumors, alongside preclinical and discovery-stage programs. Partnerships include Roche and Genentech, Sanofi, Bayer, and Merck KGaA, with collaborations involving data generation and drug programs. The integration of Exscientia expanded its chemistry capabilities, including AI-enabled molecular design and synthesis.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SALT LAKE CITY, UT
- Fiscal year end
- December
- CIK
- 1601830
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Recursion Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Recursion Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Recursion Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Recursion Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Recursion Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”